Gilead’s CAR-T Product Yescarta Results
Kite, a Gilead (GILD) subsidiary, announced new data from the ZUMA-1 trial of the CAR T Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. The data from the pivotal phase 2 study demonstrate that patients with refractory large B cell lymphoma were alive three years following a single infusion of Gilead’s CAR T immuno-oncology product Yescarta.
Analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events demonstrate steroids have succeeded in improving the adverse events.
The data were presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, FL from December 7–10, 2019.